The Krka Group's Strategy the basis of our development

Our development strategy is drawn up for a five-year period. Due to adapting to ever-changing business circumstances it is updated every two years.

Key strategic objectives until 2022

  • To attain at least 5% average annual sales growth in terms of quantities/value.
  • To ensure sufficient quantities of manufactured products in line with sales market needs, in a timely manner: through an efficient and optimised development-and-production chain that is in accordance with the required quality standards.
  • Focus on maximising long-term profitability of the sold products from development and production to sales of finished products, including all other functions within the Krka Group.
  • To ensure, in addition to the organic growth, growth also by acquisitions and long-term corporate alliances, including joint ventures, should interesting and available target companies be available. The primary goals are to secure new products and/or markets.
  • To maintain the largest possible share of new products in total sales and the share of vertically integrated products in addition to the existing range of products, also referred to as 'the golden standard'.
  • To launch the selected product portfolio onto selected key target markets as the first generic pharmaceutical company.
  • To strengthen the competitive advantage of our product portfolio;
  • To improve cost-effective use of all assets.
  • To increase innovation level across all business functions.
  • To remain independent.